“Development of the screening platform for SGLT1 inhibitor in finding novel treatment for type 2 diabetes”

Chawin Limsuwon, Sunhapas Soodvilai, Suparerk Borwornpinyo, Nisa Patikarnmonthon

 

Diabetes is a group of chronic diseases which is now being more common in people around the world. Diabetes can be categorized into two types, type 1 and type 2. Type 1 diabetes is caused by the insufficient amount of insulin production whereas Type 2 diabetes is caused by ineffective usage of insulin. These two types of diabetes lead to an excess of glucose in the bloodstream (hyperglycemia). Prolong of high glucose in the bloodstream can cause several problems such as eyes and kidneys damage, heart disease, stroke, and nerve disorders.

Previous study suggests that two types of Sodium-coupled glucose co-transporters (SGLTs), SGLT1 and SGLT2, play an important role in the absorption of glucose in intestine and reabsorption of glucose in kidney. SGLT1 and SGLT2 inhibitors can be used to control the activity of those proteins in order to reduce the amount of glucose uptake in the cells. However, the screening system of SGLT1 inhibitor for treatment of diabetes is not well established according to the low level of SGLT1 expression. Therefore, this work will be focused on the developing the screening platform for SGLT1 inhibitor. The cell culture condition will be optimized to obtain the highest SGLT1 expression. Cell will be cultured in four different conditions to examine the effect of glucose uptake of GLUT, SGLTs and SGLT1. Those conditions will then be used to establish the screening platform for dose response of SGLT1 inhibitor.

 

KEYWORD: type 2 diabetes, SGLT1, inhibitor, screening platform

Advertisements

Comments are closed.